Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm, Indica Enter Comarketing Agreement for Digital Pathology

NEW YORK (GenomeWeb) – Fluidigm and Indica Labs said today they have entered a co-marketing relationship for their digital pathology image analysis and management tools.

Under the agreement, the two companies will cooperatively promote Indica's HALO image analysis products with Fluidigm's Hyperion imaging mass cytometry platform and related reagents and software.

"The Hyperion Imaging System combined with our HALO image analysis capabilities represents a complete solution for multiplexing, especially in immuno-oncology, where the requirement for higher-multiplexed imaging data is on the rise," Indica CEO Steven Hashagen said in a statement.

Chris Linthwaite, president and CEO of Fluidigm, added that the agreement "provides our customers in oncology, immuno-oncology, and other critical research areas another tool to drive meaningful insights in health and disease."

Fluidgm's imaging mass cytometry technology allows researchers to profile dozens of proteins across millions of cells at the single-cell level, while Indica's HALO supports analysis of highly multiplexed tissue biomarker and cellular phenotype data.

Financial and other terms of the agreement were not disclosed.